Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study

By Hill Simon   Elhilali Mostafa   Millard Richard J   Dwyer Peter L   Lheritier Karine   Kawakami Fernando T.   Steel Michael  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2697-2704

Informa Healthcare

Access to resources Recommend Favorite

Tolerability of solifenacin and oxybutynin immediate release in older (>65 years) and younger (≤65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study

By Herschorn S.   Pommerville P.   Stothers L.   Egerdie B.   Gajewski J.   Carlson K.   Radomski S.   Drutz H.   Schulz J.   Barkin J.   Hirshberg E.   Corcos J.  

Current Medical Research and Opinion, Vol. 27, Iss. 2, 2011-02 ,pp. : 375-382

Informa Healthcare

Access to resources Recommend Favorite

Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial

By Chapple C   DuBeau C   Ebinger U   Rekeda L   Viegas A  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2347-2358

Informa Healthcare

Access to resources Recommend Favorite

Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder

By Corcos Jacques   Angulo Javier C.   Garely Alan D.   Carlsson Martin   Gong Jason   Guan Zhonghong  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 1059-1065

Informa Healthcare

Access to resources Recommend Favorite

Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms

By Scarpero Harriette   Sand Peter K.   Kelleher Con J.   Berriman Sandra   Bavendam Tamara   Carlsson Martin  

Current Medical Research and Opinion, Vol. 27, Iss. 5, 2011-05 ,pp. : 921-930

Informa Healthcare

Access to resources Recommend Favorite